Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | -1.20% | |
Stochastic Reached Overbought | Strength | -1.20% | |
Weak + Overbought | Other | -1.20% | |
BB Squeeze + Upper Band Touch | Range Contraction | -1.20% | |
Outside Day | Range Expansion | -1.20% | |
Above Upper BB | Strength | -1.20% | |
Overbought Stochastic | Strength | -1.20% | |
Upper Bollinger Band Touch | Strength | -1.20% | |
New Uptrend | Bullish | 0.38% | |
Bollinger Band Squeeze | Range Contraction | 0.38% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 9 minutes ago |
Down 1% | 40 minutes ago |
Fell Below Upper Bollinger Band | about 1 hour ago |
Up 2% | about 22 hours ago |
60 Minute Opening Range Breakout | about 23 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Hemoglobin Huntington's Disease Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Hemoglobinopathies Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 218.88 |
52 Week Low | 143.52 |
Average Volume | 929,833 |
200-Day Moving Average | 177.63 |
50-Day Moving Average | 161.83 |
20-Day Moving Average | 149.49 |
10-Day Moving Average | 149.29 |
Average True Range | 4.60 |
RSI (14) | 52.15 |
ADX | 25.73 |
+DI | 23.36 |
-DI | 19.89 |
Chandelier Exit (Long, 3 ATRs) | 147.51 |
Chandelier Exit (Short, 3 ATRs) | 157.46 |
Upper Bollinger Bands | 153.62 |
Lower Bollinger Band | 145.36 |
Percent B (%b) | 1.09 |
BandWidth | 5.53 |
MACD Line | -2.73 |
MACD Signal Line | -4.21 |
MACD Histogram | 1.4882 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 161.71 | ||||
Resistance 3 (R3) | 161.19 | 158.24 | 160.49 | ||
Resistance 2 (R2) | 158.24 | 156.37 | 158.50 | 160.08 | |
Resistance 1 (R1) | 156.31 | 155.22 | 157.28 | 156.83 | 159.68 |
Pivot Point | 153.36 | 153.36 | 153.84 | 153.62 | 153.36 |
Support 1 (S1) | 151.43 | 151.49 | 152.40 | 151.95 | 149.10 |
Support 2 (S2) | 148.48 | 150.34 | 148.74 | 148.70 | |
Support 3 (S3) | 146.55 | 148.48 | 148.29 | ||
Support 4 (S4) | 147.07 |